SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2024-07-29
Accession Number: 0001013762-24-002165
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000101376224002165/ea020832402ex1-1_synergy.htm

Chunk 8 of 15
Word Count: 1429
Character Count: 9149

Document Content:

execute a general consent to service of process in any state or to subject itself to taxation in respect of doing business in any jurisdiction in which it is not otherwise subject. The Company will furnish to the Underwriters and counsel to the Underwriters copies of the Registration Statement, each Prospectus, any Issuer Free Writing Prospectus, and all amendments and supplements to such documents, in each case as soon as available and in such quantities as the Underwriters may from time to time reasonably request. (vii) The Company will make generally available to its security holders as soon as practicable, but in any event not later than 15 months after the end of the Company’s current fiscal quarter, an earnings statement (which need not be audited) covering a 12-month period that shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.

(viii)
The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause
to be paid (A) all expenses (including transfer taxes allocated to the respective transferees) incurred in connection with the delivery
to the Underwriters of the Securities (including all fees and expenses of the registrar and transfer agent of the Shares and the registrar
and transfer agent of the Underwriter Warrants (if other than the Company), and the cost of preparing and printing stock certificates
and warrant certificates), (B) all expenses and fees (including, without limitation, fees and expenses of the Company’s counsel)
in connection with the preparation, printing, filing, delivery, and shipping of the Registration Statement (including the financial statements
therein and all amendments, schedules, and exhibits thereto), the Securities, the Time of Sale Disclosure Package, any Prospectus, the
Final Prospectus, any Issuer Free Writing Prospectus and any amendment thereof or supplement thereto, (C) all reasonable filing fees
and reasonable fees and disbursements of the Underwriters’ counsel incurred in connection with the qualification of the Shares
for offering and sale by the Underwriters or by dealers under the securities or blue sky laws of the states and other jurisdictions that
the Representative shall designate, (D) the reasonable filing fees and reasonable fees and disbursements of counsel to the Underwriters
incident to any required review and approval by FINRA, of the terms of the sale of the Shares, (F) listing fees, if any, and (G) all
other costs and expenses incident to the performance of its obligations hereunder that are not otherwise specifically provided for herein.
On the Closing Date, the Company will reimburse the Representative for the Underwriters’ reasonable out-of-pocket expenses, including
legal fees and disbursements, in connection with the purchase and sale of the Securities contemplated hereby up to an aggregate of $325,000
(including amounts payable pursuant to clauses (C) and (D) above);. If this Agreement is terminated by the Representative in accordance
with the provisions of Section 6, Section 9 or Section 11, the Company will reimburse the Underwriters for all out-of-pocket disbursements
(including, but not limited to, reasonable fees and disbursements of counsel, travel expenses, postage, facsimile and telephone charges)
incurred by the Underwriters in connection with their investigation, preparing to market and marketing the Shares or in contemplation
of performing their obligations hereunder in an amount which shall not exceed $75,000 in the aggregate.

The Company intends to apply the net proceeds from the sale of the Shares to be sold by it hereunder for the purposes set forth in the
Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus under the heading “Use of Proceeds”.

The Company has not taken and will not take, directly or indirectly, during the Prospectus Delivery Period, any action designed to or
which might reasonably be expected to cause or result in, or that has constituted, the stabilization or manipulation of the price of
any security of the Company to facilitate the sale or resale of the Shares.

The Company represents and agrees that, unless it obtains the prior written consent of the Representative, and the each Underwriter,
severally, and not jointly, represents and agrees that, unless it obtains the prior written consent of the Company, it has not made and
will not make any offer relating to the Shares that would constitute an Issuer Free Writing Prospectus; provided that the prior written
consent of the parties hereto shall be deemed to have been given in respect of the free writing prospectuses included in Schedule
III. Any such free writing prospectus consented to by the Company and the Representative is hereinafter referred to as a “Permitted
Free Writing Prospectus.” The Company represents that it has treated or agrees that it will treat each Permitted Free Writing
Prospectus as an “issuer free writing prospectus,” as defined in Rule 433, and has complied or will comply with the requirements
of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely Commission filing where required, legending and record-keeping.

(xii)
The Company hereby agrees that, without the prior written consent of the Representative, it will not, during the period ending ninety
(90) days after the date hereof (“Lock-Up Period”), (i) offer, pledge, issue, sell, contract to sell, purchase, contract
to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible
into or exercisable or exchangeable for Common Stock; or (ii) enter into any swap or other arrangement that transfers to another, in
whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described in clause
(i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise; or (iii) file any registration
statement with the Commission relating to the offering of any shares of Common Stock or any securities convertible into or exercisable
or exchangeable for Common Stock. The restrictions contained in the preceding sentence shall not apply to (1) the Shares to be sold hereunder,
(2) the issuance of Common Stock upon the exercise of options or warrants or the conversion of outstanding preferred stock or other outstanding
convertible securities disclosed as outstanding in the Registration Statement (excluding exhibits thereto), the Time of Sale Disclosure
Package, and the Final Prospectus, (3) the issuance of employee stock options not exercisable during the Lock-Up Period and the grant
of restricted stock awards or restricted stock units or shares of Common Stock pursuant to equity incentive plans described in the Registration
Statement (excluding exhibits thereto), the Time of Sale Disclosure Package, and the Final Prospectus, (4) the filing of a registration
statement on Form S-8, (5) the entry into an agreement providing for the issuance of Common Stock or any security convertible into or
exercisable for shares of Common Stock in connection with an acquisition by the Company or its subsidiaries of the securities, business,
technology, property or other assets of another person or entity, and the issuance of any such securities pursuant to any such agreement
or (6) the entry into an agreement providing for the issuance of Common Stock or any security convertible into or exercisable for shares
of Common Stock in connection with joint ventures, commercial relationships or other strategic transactions, and the issuance of any
such securities pursuant to any such agreement.

(xiii)
The Company hereby agrees, during a period of three years from the effective date of the Registration Statement, to furnish to the Representative
copies of all reports or other communications (financial or other) furnished to shareholders, and to deliver to the Representative as
soon as reasonably practicable upon availability, copies of any reports and financial statements furnished to or filed with the Commission
or any national securities exchange on which any class of securities of the Company is listed; provided, that any information or documents
available on the Commission’s Electronic Data Gathering, Analysis and Retrieval System shall be considered furnished for purposes
of this Section 5(a)(xiii).

(xiv)
The Company hereby agrees to engage and maintain, at its expense, a registrar and transfer agent for the Common Stock (if other than
the Company).

The Company hereby agrees to use its reasonable best efforts to obtain approval to list the Shares and the Underwriter Warrant Shares
on the Nasdaq.

(xvi)
The Company hereby agrees not to take, directly or indirectly, any action designed to cause or result in, or that has constituted or
might reasonably be expected to constitute, under the Exchange Act or otherwise, the stabilization or manipulation of the price of any
securities of the Company to facilitate the sale or resale of the Shares.